A Clinician’s Guide to Cancer Therapy-Related Cardiovascular Toxicity
- 1Cardio-Oncology and Amyloid Program, Division of Cardiology, Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL 62702, USA
Abstract
Advances in cancer therapy have substantially improved survival, resulting in a rapidly growing population of cancer survivors. Consequently, cardiovascular disease has emerged as a major determinant of long-term morbidity and mortality, establishing cancer therapy-related cardiovascular toxicity as a central challenge in contemporary cardio-oncology. Modern oncologic therapies produce a broad spectrum of cardiovascular complications, including heart failure, arrhythmias, myocarditis, vascular toxicity, thromboembolic disease, valvular abnormalities, pulmonary hypertension, and autonomic dysfunction. These toxicities arise through diverse mechanisms, including direct myocardial injury, endothelial dysfunction, immune-mediated inflammation, cytokine excess, metabolic derangements, and neurohormonal alterations. This review provides a clinician-oriented, mechanism-based overview of cancer therapy-related cardiovascular toxicity in the modern era. Major therapeutic classes are discussed, including anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cell therapies, radiation therapy, endocrine therapies, and emerging targeted agents. The review also highlights evolving cardiovascular toxicity phenotypes, radiation-induced heart disease, and the growing relevance of cardiac amyloidosis within the cardio-oncology spectrum. Moreover, contemporary strategies for cardiovascular risk assessment, imaging and biomarker surveillance, cardioprotection, and therapy-specific management are reviewed, with an emphasis on practical clinical application. Finally, current knowledge gaps, survivorship considerations, and future directions are discussed, including artificial intelligence-assisted risk stratification. Overall, by integrating mechanistic understanding with practical management frameworks, this review aims to provide clinicians with a comprehensive resource for the prevention, detection, and treatment of cardiovascular complications associated with modern cancer therapies.
Related
- Precision Cardio-Oncology: A Multimodal Approach to Cancer Therapy-Related Cardiovascular Toxicity Prediction and Assessment
- Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
- Cardiovascular Magnetic Resonance for Early Detection of Cancer Therapy-Related Cardiac Dysfunction: From Multiparametric Tissue Signatures to Clinical Pathways
- Surviving cancer, managing the heart: Awareness of potential cardiovascular toxicity and barriers to cardiovascular self-management among women with breast cancer: A qualitative descriptive study
- Theranekron Attenuates Inflammation, Oxidative Stress Index, and Apoptosis in Lipopolysaccharide‐Induced Cardiovascular Toxicity: Association With Hypoxia‐Inducible Factor‐1 Alpha‐Related Gene Expression
BibTeX
@article{bhattarai2026clinicians,
title = {{A Clinician’s Guide to Cancer Therapy-Related Cardiovascular Toxicity}},
author = {Mukul Bhattarai},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm54342},
url = {https://doi.org/10.31083/rcm54342},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A Clinician’s Guide to Cancer Therapy-Related Cardiovascular Toxicity
AU - Mukul Bhattarai
PY - 2026
DA - 2026/10/16
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm54342
UR - https://doi.org/10.31083/rcm54342
AB - Advances in cancer therapy have substantially improved survival, resulting in a rapidly growing population of cancer survivors. Consequently, cardiovascular disease has emerged as a major determinant of long-term morbidity and mortality, establishing cancer therapy-related cardiovascular toxicity as a central challenge in contemporary cardio-oncology. Modern oncologic therapies produce a broad spectrum of cardiovascular complications, including heart failure, arrhythmias, myocarditis, vascular toxicity, thromboembolic disease, valvular abnormalities, pulmonary hypertension, and autonomic dysfunction. These toxicities arise through diverse mechanisms, including direct myocardial injury, endothelial dysfunction, immune-mediated inflammation, cytokine excess, metabolic derangements, and neurohormonal alterations. This review provides a clinician-oriented, mechanism-based overview of cancer therapy-related cardiovascular toxicity in the modern era. Major therapeutic classes are discussed, including anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cell therapies, radiation therapy, endocrine therapies, and emerging targeted agents. The review also highlights evolving cardiovascular toxicity phenotypes, radiation-induced heart disease, and the growing relevance of cardiac amyloidosis within the cardio-oncology spectrum. Moreover, contemporary strategies for cardiovascular risk assessment, imaging and biomarker surveillance, cardioprotection, and therapy-specific management are reviewed, with an emphasis on practical clinical application. Finally, current knowledge gaps, survivorship considerations, and future directions are discussed, including artificial intelligence-assisted risk stratification. Overall, by integrating mechanistic understanding with practical management frameworks, this review aims to provide clinicians with a comprehensive resource for the prevention, detection, and treatment of cardiovascular complications associated with modern cancer therapies.
SN - 1530-6550
SN - 2153-8174
ER -